Impact Biomedical (IBO) Operating Expenses (2022 - 2026)
Impact Biomedical's (IBO) quarterly Operating Expenses came in at $2.3 million in Q1 2026, up 127.33% YoY from $1.0 million in Q1 2025, and up 618.28% on a QoQ basis from -$443000.0 in Q4 2025.
Impact Biomedical (IBO) Operating Expenses (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Operating Expenses data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Operating Expenses rose 127.33% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 86.28% YoY) and the FY2025 annual result came in at $312000.0, down 98.91% from the prior year.
- Operating Expenses rose to $2.3 million in Q1 2026, from -$443000.0 in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $26.2 million in Q4 2024 to a low of -$443000.0 in Q4 2025.
- A 5-year average of $2.5 million and a median of $1.0 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 2202.99% — and 2025, when it sank 101.69%.
- Tracing IBO's Operating Expenses over 5 years: stood at $1.0 million in 2022, then rose by 10.37% to $1.1 million in 2023, then surged by 2202.99% to $26.2 million in 2024, then plunged by 101.69% to -$443000.0 in 2025, then surged by 618.28% to $2.3 million in 2026.
- The last three Operating Expenses figures came in at $2.3 million (Q1 2026), -$443000.0 (Q4 2025), and $966000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Impact Biomedical | 49.45 Mn | 49.44 Mn | 2,000.00 | 705,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 705,000.00 |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | -443,000.00 |
| Sep 30, 2025 | 966,000.00 |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 26.23 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 626,000.00 |
| Mar 31, 2024 | 771,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 803,000.00 |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 889,000.00 |
| Jun 30, 2022 | 800,000.00 |